Two IPO debuts underscored strong investor appetite for late-stage-ready and category-defining specialties. Seaport Therapeutics and Hemab Therapeutics entered public markets through a combined fundraising sweep totaling $556 million, continuing an active IPO window for drugmakers. Avalyn Pharma then followed with an upsized $300 million IPO to fund inhaled drug development for pulmonary fibrosis. The financing is positioned to support late-stage progress for reformulated respiratory candidates already approved in other indications. The combined flow matters for biotech planning because it reflects both demand for liquidity and confidence in development-stage execution—especially in respiratory and immunology-adjacent spaces.